Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: A California Cancer Consortium trial

British Journal of Haematology

Volumn 154, Issue 4, 2011, Pages 533-535

  Somlo, George ^a   Lashkari, Ashkan ^a   Bellamy, William ^b   Zimmerman, Todd M ^c   Tuscano, Joseph M ^d   O'Donnell, Margaret R ^a   Mohrbacher, Ann F ^e   Forman, Stephen J ^a   Frankel, Paul ^f   Chen, Helen X ^g   Doroshow, James H ^g   Gandara, David R ^d  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f University of Southern California ^*  (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Bevacizumab; Multiple myeloma; Thalidomide; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; AUTOTRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FATIGUE; FEMALE; HUMAN; HYPERTENSION; HYPONATREMIA; LETTER; LYMPHOCYTOPENIA; MALE; MONOTHERAPY; MULTIPLE MYELOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960846565     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08623.x     Document Type: Letter

References (10)

1. Du, W., Hattori, Y., Hashiguchi, A., Kondoh, K., Hozumi, N., Ikeda, Y., Sakamoto, M., Hata, J. & Yamada, T. (2004) Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathology International, 54, 285-294.
2. Durie, B.G. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842-854.
3. Hideshima, T., Podar, K., Chauhan, D. & Anderson, K.C. (2005) Cytokines and signal transduction. Best Practice & Research. Clinical Haematology, 18, 509-524.
4. Jenab-Wolcott, J. & Giantonio, B.J. (2009) Bevacizumab: current indications and future development for management of solid tumors. Expert Opinion On Biological Therapy, 9, 507-517.
5. Knight, R. (2005) IMiDs: a novel class of immunomodulators. Seminars in Oncology, 32, S24-S30.
6. Lu, L., Payvandi, F., Wu, L., Zhang, L.H., Hariri, R.J., Man, H.W., Chen, R.S., Muller, G.W., Hughes, C.C., Stirling, D.I., Schafer, P.H. & Bartlett, J.B. (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvascular Research, 77, 78-86.
7. Moschetta, M., Di Pietro, G., Ria, R., Gnoni, A., Mangialardi, G., Guarini, A., Ditonno, P., Musto, P., D'Auria, F., Ricciardi, M.R., Dammacco, F., Ribatti, D. & Vacca, A. (2010) Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. European Journal of Cancer, 46, 420-429.
8. Pittini, V., Teti, D., Arrigo, C., Aloi, G. & Righi, M. (2002) Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF. British Journal of Haematology, 119, 275.
9. Ribatti, D. & Vacca, A. (2003) On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma. Annals of Hematology, 82, 262.
10. Roccaro, A.M., Hideshima, T., Raje, N., Kumar, S., Ishitsuka, K., Yasui, H., Shiraishi, N., Ribatti, D., Nico, B., Vacca, A., Dammacco, F., Richardson, P.G. & Anderson, K.C. (2006) Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Research, 66, 184-191.